Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023

SELL
$27.57 - $32.91 $129,579 - $154,676
-4,700 Reduced 16.85%
23,200 $639,000
Q2 2023

Aug 07, 2023

BUY
$29.91 - $38.73 $834,489 - $1.08 Million
27,900 New
27,900 $840,000
Q4 2020

Feb 11, 2021

SELL
$17.7 - $25.81 $123,900 - $180,670
-7,000 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$20.2 - $25.05 $141,400 - $175,350
7,000 New
7,000 $146,000
Q1 2020

May 13, 2020

SELL
$14.45 - $24.69 $1.09 Million - $1.85 Million
-75,100 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$19.93 - $29.13 $83,706 - $122,346
4,200 Added 5.92%
75,100 $1.78 Million
Q3 2019

Nov 08, 2019

SELL
$25.47 - $33.37 $2,547 - $3,336
-100 Reduced 0.14%
70,900 $1.95 Million
Q2 2019

Aug 09, 2019

SELL
$29.96 - $38.87 $290,612 - $377,039
-9,700 Reduced 12.02%
71,000 $2.35 Million
Q1 2019

May 15, 2019

BUY
$32.77 - $41.99 $183,512 - $235,144
5,600 Added 7.46%
80,700 $2.83 Million
Q4 2018

Feb 12, 2019

SELL
$30.84 - $49.51 $67,848 - $108,922
-2,200 Reduced 2.85%
75,100 $2.5 Million
Q3 2018

Nov 05, 2018

BUY
$42.7 - $56.55 $1.12 Million - $1.48 Million
26,200 Added 51.27%
77,300 $3.89 Million
Q2 2018

Aug 14, 2018

SELL
$44.1 - $59.85 $590,940 - $801,990
-13,400 Reduced 20.78%
51,100 $3.06 Million
Q1 2018

Apr 30, 2018

SELL
$37.15 - $46.9 $542,390 - $684,740
-14,600 Reduced 18.46%
64,500 $2.95 Million
Q4 2017

Feb 12, 2018

BUY
$36.4 - $42.6 $2.88 Million - $3.37 Million
79,100
79,100 $3.15 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.93B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Skandinaviska Enskilda Banken Ab (Publ) Portfolio

Follow Skandinaviska Enskilda Banken Ab (Publ) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

News

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.